Blood Stem Cell Transplantation for the Treatment of Older Patients With Acute Myelogenous Leukemia

Inclusion Criteria:

For Study Registration:

Age 55 - 70 years.
Subjects diagnosed with AML (> 20% myeloblasts).

For Proceeding to Transplant:

Subjects must be in either complete remission (CR) or partial remission (PR) within 14 days prior to admission.
Subjects must be > 21 days since completion of prior systemic chemotherapy or radiation therapy (including craniospinal XRT), prior to admission .

Organ function requirements for a reduced intensity (FluBu2) regimen (must be met within 21 days of admission):

Cardiac: LV Ejection Fraction > 40% on MUGA or Echocardiogram.
Pulmonary: FEV1 and FVC > 40% predicted, DLCO > 40% of predicted.
Renal: Serum creatinine < 2.0 mg/dl. Not on hemodialysis or continuous veno-venous filtration (CVVH).
Hepatic: serum total bilirubin < 3.0 mg/dl and AST / ALT < 4x ULN
Karnofsky > 60%.

Organ function requirements for a full intensity (FluBu4) regimen (must be met within 21 days of admission):

Cardiac: LV Ejection Fraction > 40% on MUGA or Echocardiogram.
Pulmonary: FEV1 and FVC > 50% predicted, DLCO (corrected for hemoglobin) > 50% of predicted.
Renal: serum creatinine < 2.0 mg/dl. Not on hemodialysis or continuous veno-venous filtration (CVVH)
Hepatic: serum total bilirubin < 3.0 mg/dl and AST / ALT < 4x ULN.
Karnofsky > 60%.

Exclusion Criteria:

For Study Registration:

Subjects with M3 AML (FAB classification)

For Proceeding to Transplant:

Subjects who exhibit signs of progressive disease (> 20% blasts) within 14 days prior to admission for transplant
Patients with an uncontrolled viral or fungal infection within the prior 28 days.
Patients who are HIV1 or HIV2 positive.
Uncontrollable medical or psychiatric disorder